Why Halozyme Therapeutics, Inc. (HALO) stock moved
Halozyme Therapeutics, Inc. (HALO) shares fell 0.9% to $77.09 as of July 21, 2026, a slight decline from the prior close of $77.81. BestStocks flagged the session as a major change for HALO. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for HALO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HALO fell 0.9% to $77.09
Halozyme Therapeutics, Inc. (HALO) moved −3.08% from $78.62 to $76.20 on 2026-07-10. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Monitor for the next earnings release or material news announcement to determine if the decline represents a tactical pullback or signals deteriorating sentiment.
What it means for Halozyme Therapeutics, Inc. investors
For Halozyme Therapeutics, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: HALO moved +1.67% from $79.45 to $80.78 on 2026-07-06; Halozyme Therapeutics, Inc. (HALO) moved +3.17% from $77.01 to $79.45 on 2026-07-02. Weighing against that: Negative session, down 0.9%; Halozyme Therapeutics, Inc. (HALO) moved −3.08% from $78.62 to $76.20 on 2026-07-10. Wall Street's consensus price target sits at $88.25, implying +14.5% upside from $77.09. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
HALO price reaction
HALO last traded at $77.09, down $0.72 (-0.93%) from the previous close of $77.81. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $68.99 and $81.57, and it currently sits about 64% of the way up that band.
Bullish and bearish analyst opinions on Halozyme Therapeutics, Inc. (HALO)
The consensus analyst price target on Halozyme Therapeutics, Inc. (HALO) is $88.25, 14.5% above the recent $77.09. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HALO line up.
The bullish case
- Wall Street's consensus price target of $88.25 implies +14.5% upside from $77.09.
- The Street's most bullish target is $95.00 (+23.2%).
- HALO moved +1.67% from $79.45 to $80.78 on 2026-07-06.
- Halozyme Therapeutics, Inc. (HALO) moved +3.17% from $77.01 to $79.45 on 2026-07-02.
The bearish case
- The most bearish analyst target is $75.00 (-2.7%).
- Negative session, down 0.9%.
- Halozyme Therapeutics, Inc. (HALO) moved −3.08% from $78.62 to $76.20 on 2026-07-10.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HALO
Frequently asked questions about HALO
Why did Halozyme Therapeutics, Inc. (HALO) stock move?
HALO fell 0.9% to $77.09. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did HALO stock fall?
HALO lost 0.93% ($0.72) versus the prior close of $77.81, last trading at $77.09 on 0.8× average volume.
When is Halozyme Therapeutics, Inc.'s next earnings date?
HALO's next earnings report is estimated for 2026-08-04 — about 14 days away.
What is the analyst price target for HALO?
The consensus analyst price target for HALO is $88.25, about 14.5% above the current $77.09. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks HALO
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared HALO-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for HALO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.